Delving into the Latest Updates on Suzhou Southeast Pharmaceuticals Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Infectious Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Hepatitis C virus NS 5 protein	1

The purpose of this study is to refer to the bioequivalence evaluation method to study the bioavailability and pharmacokinetic characteristics of TQ-A3326 tablets provided by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Baili ZeTM produced by AstraZeneca Pharmaceuticals LP in healthy adult subjects, in order to support the registration application of TQ-A3326 tablets.

Start Date25 Jan 2021

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

[+1]

100 Clinical Results associated with Suzhou Southeast Pharmaceuticals Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Suzhou Southeast Pharmaceuticals Co., Ltd.

Login to view more data

100 Deals associated with Suzhou Southeast Pharmaceuticals Co., Ltd.

Login to view more data

100 Translational Medicine associated with Suzhou Southeast Pharmaceuticals Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Apr 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Other

Login to view more data